Want to see MHUAF full AI Analyst Report?
Meihua International Medical Technologies Co Ltd (MHUAF) AI Stock Analysis
Top Page
Meihua International Medical Technologies Co Ltd
(Other OTC:MHUAF)
The score is driven mainly by mixed financial performance: a strong, conservatively financed balance sheet is offset by a clear 2025 operating downshift and highly volatile cash generation. Technical indicators also weigh on the score due to bearish trend/momentum. These risks are partially balanced by an extremely low P/E valuation metric.
Meihua International Medical Technologies Co Ltd (MHUAF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 704
- Price to Earnings (P/E)
- 0.5
- Beta (1Y)
- 0.81
- Revenue Growth
- -36.24%
- EPS Growth
- -61.74%
- Country
- US
- Employees
- 486
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Meihua International Medical Technologies Co Ltd Business Overview & Revenue Model
Company Description
Meihua International Medical Technologies Co., Ltd. is a Chinese company dedicated to the innovation, production, and distribution of a wide array of medical devices. Operating primarily within the People's Republic of China, its comprehensive produc...
How the Company Makes Money
The company primarily makes money by selling medical devices and medical consumables to healthcare providers and medical supply distributors. Key revenue is generated from (1) product sales of disposable medical supplies (recurring demand driven by s...
Meihua International Medical Technologies Co Ltd Financial Statement Overview
Summary
Mixed fundamentals: a very strong, low-leverage balance sheet supports resilience, but operating performance weakened materially in 2025 (sharp revenue decline, margin compression, and lower net income). Cash flow is a key concern due to volatility and a steep drop in 2025 operating/free cash flow versus 2024.
Income Statement
46NeutralBalance Sheet
82Very PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.79M | 61.79M | 96.91M | 97.10M | 103.35M | 104.04M |
| Gross Profit | 19.08M | 18.99M | 33.30M | 33.09M | 38.10M | 39.81M |
| EBITDA | 8.83M | 8.83M | 15.70M | 15.77M | 11.65M | 27.03M |
| Net Income | 6.78M | 6.78M | 10.84M | 11.63M | 6.24M | 20.95M |
Balance Sheet | ||||||
| Total Assets | 207.18M | 207.18M | 186.24M | 171.92M | 163.58M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 15.15M | 15.15M | 15.96M | 16.93M | 26.74M | 8.15M |
| Total Debt | 8.99M | 8.99M | 7.95M | 7.33M | 6.81M | 5.18M |
| Total Liabilities | 18.25M | 18.25M | 27.26M | 25.08M | 24.90M | 29.09M |
| Stockholders Equity | 188.93M | 188.93M | 158.98M | 146.33M | 138.12M | 106.81M |
Cash Flow | ||||||
| Free Cash Flow | 554.25K | 554.25K | 14.50M | -2.41M | -11.86M | -904.89K |
| Operating Cash Flow | 569.88K | 569.88K | 14.64M | 2.28M | -9.16M | -54.66K |
| Investing Cash Flow | -20.13M | -20.13M | -20.42M | -12.46M | -8.62M | -833.82K |
| Financing Cash Flow | 17.19M | 17.19M | 6.21M | 706.13K | 37.25M | 1.86M |
Meihua International Medical Technologies Co Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MHUAF, the sentiment is Neutral. The current price of 6.90 is above the 20-day moving average (MA) of 6.77, below the 50-day MA of 6.95, and below the 200-day MA of 8.01, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 53.65 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MHUAF.
Meihua International Medical Technologies Co Ltd Risk Analysis
Meihua International Medical Technologies Co Ltd disclosed 80 risk factors in its most recent earnings report. Meihua International Medical Technologies Co Ltd reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMeihua International Medical Technologies Co Ltd Peers Comparison
Overall Rating
- MHUAF58Neutral
WOK43Neutral
GCTK39Underperform
LUCY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MHUAF | 58Neutral | $5.92M | 0.45 | 3.83% | ― | -36.24% | -61.74% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| WOK | 43Neutral | $4.47M | -0.00 | -18.55% | ― | ― | ― |
| GCTK | 39Underperform | $959.14K | -0.00 | -2135.52% | ― | ― | 99.51% |
| LUCY | 38Underperform | $7.24M | -0.61 | -88.90% | ― | 72.50% | 58.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MHUAF | Meihua International Medical Technologies Co., Ltd. | 6.90 | -15.72 | -69.50% | |
| GCTK | Glucotrack, Inc. | 0.81 | -192.99 | -99.58% | |
| LUCY | Innovative Eyewear, Inc. | 0.83 | -0.88 | -51.46% | |
| WOK | WORK Medical Technology Group LTD | 1.00 | -32799.00 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026